2026-01-23 - Analysis Report
**Company Overview**
Morgan Stanley is a multinational investment bank and financial services company.

**Return Rate Comparison**

* Return rate of MS: 156.87%
* Return rate of S&P 500 (VOO): 92.53%
* Divergence from comparison stock: 64.34%

The return rate of MS is significantly higher than that of S&P 500, indicating a higher level of risk.

**Alpha, Beta Analysis**

| Year | CAGR | MDD | Alpha | Beta | Cap(B) |
|------|------|------|-------|------|-------|
| 2016-2018 | 2.0% | 20.6% | -3.0% | 1.6 | 63.0B |
| 2017-2019 | -20.0% | 20.6% | -37.0% | 1.3 | 81.2B |
| 2018-2020 | -1.0% | 25.6% | -22.0% | 1.4 | 108.9B |
| 2019-2021 | 83.0% | 25.6% | 40.0% | 1.4 | 156.0B |
| 2020-2022 | 14.0% | 36.2% | 16.0% | 1.3 | 135.1B |
| 2021-2023 | 11.0% | 36.2% | 10.0% | 1.1 | 148.2B |
| 2022-2024 | 2.0% | 32.5% | -17.0% | 1.1 | 199.8B |
| 2023-2025 | 90.0% | 24.2% | 28.0% | 1.3 | 282.1B |

The CAGR (Compound Annual Growth Rate) varies significantly across different year ranges, indicating a volatile market performance. MDD (Maximum Drawdown) also shows significant fluctuations, indicating a high risk level.

**Recent Stock Price Fluctuations**

* Close: $183.05
* Last-market change: -0.15%
* 5-day SMA: $185.76
* 20-day SMA: $183.52
* 60-day SMA: $173.74

The stock price is currently slightly below the 20-day SMA, indicating a potential downward trend. The 5-day SMA is higher than the current price, suggesting a possible rebound.

**RSI, PPO Analysis**

* MRI: 0.90 (High Investment Recommended)
* RSI: 56.57
* PPO: -0.38
* Hybrid Signal: Buy (Cash 0%)
* Risk Level: High
* Recent relative divergence change: -0.20 (worsening)
* 7-day Rank change: 12 (+)
* 7-day Dynamic Expected Return change: 0.40 (+)
* Expected Return: 4.30%

The MRI is high, indicating a recommended investment. The RSI is relatively low, suggesting a potential buying opportunity. The PPO is negative, indicating a sell signal. The recent relative divergence change is worsening, indicating a potential decrease in performance.

**Recent News & Significant Events**

* [2026-01-22] Andrew Saperstein Sells 30,330 Shares of Morgan Stanley (NYSE:MS) Stock - MarketBeat (news.google.com)
* [2026-01-22] Microsoft Stock To $350? - Forbes (news.google.com)
* [2026-01-22] Microsoft Stock: Is the AI Investment Skepticism Justified? - Trefis (news.google.com)
* [2026-01-15] MORGAN STANLEY (MS) - MSN (news.google.com)
* [2026-01-21] TD Cowen Sees Microsoft (MSFT) Shares Range-Bound Ahead of Earnings - Yahoo Finance (news.google.com)
* [2026-01-22] Eric Grossman Sells 21,555 Shares of Morgan Stanley (NYSE:MS) Stock - MarketBeat (news.google.com)

**Analyst Opinions**

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 2.40 (~Buy)
- Opinions: 21
- Target Price (avg/high/low): 192.76 / 221.00 / 148.00

The analyst consensus is to buy, with a high target price range.

**Recent Earnings Analysis**

| Date | EPS | Revenue |
|----:|----:|--------:|
| 2025-10-29 | 3.73 | 77.67 B$ |
| 2025-04-30 | 3.47 | 70.07 B$ |
| 2025-01-29 | 3.24 | 69.63 B$ |
| 2024-10-30 | 3.32 | 65.58 B$ |
| 2025-10-29 | 3.32 | 65.58 B$ |

The revenue and EPS have fluctuated over the past year, indicating a volatile market performance.

**Financial Information**

| Date | Net Income | Total Expenses |
|----:|-----------:|---------------:|
| 2025-10-29 | 8.41 B$ | 69.26 B$ |
| 2025-04-30 | 8.14 B$ | 61.93 B$ |
| 2025-01-29 | 7.65 B$ | 61.98 B$ |
| 2024-10-30 | 7.53 B$ | 58.05 B$ |
| 2025-10-29 | 7.53 B$ | 58.05 B$ |

The net income and total expenses have fluctuated over the past year, indicating a volatile market performance.

**Comprehensive Analysis (Summary of previous items)**

Morgan Stanley's stock price has a high divergence from the S&P 500, indicating a higher level of risk. The CAGR and MDD show significant fluctuations, indicating a volatile market performance. The RSI and PPO indicate a potential buying opportunity, but the recent relative divergence change is worsening. The analyst consensus is to buy, with a high target price range. The revenue and EPS have fluctuated over the past year, indicating a volatile market performance.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.